Two Standards of Care
While improved treatments are necessary for all people living with hepatitis C, this is particularly true for people who are living with HIV/HCV co-infection. Procedural and institutional barriers have resulted in two standards of care – one for people living with mono-infection, and a much worse standard for people living with co-infection. This position paper explains why these two standards of care have emerged and makes pragmatic recommendations to accelerate clinical trials and Common Drug Review decision-making to allow co-infected people to benefit from the latest technologies available.
This position paper explains:
- How clinical trial designs often cause unnecessary delays in evaluating the safety and efficacy of newhepatitis C treatments for people who are living with co-infection
- How health technology assessment organizations like the Common Drug Review, as well as public formularies, exacerbate these delays by limiting coverage for co-infected people, preventing doctors from doing what is right for their patients.
- Pragmatic changes that can be made to clinical trial designs and health technology assessment decision-making that will assure timely access and equitable treatment for people living with co-infection
Read and download the report here.
Two Standards of Care: Toward Treatment Equity for People Living With HIV/HCV Co-Infection by Paul Sutton is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.